Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
Study Identifier:
ALXN1210-PNH-401
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Eculizumab
- Biological: Ravulizumab
Date
Apr 2021 - Dec 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Eculizumab
- Biological: Ravulizumab
Date
Apr 2021 - Dec 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
The primary purpose of this study is to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab in participants who are prescribed and are receiving a higher than approved dose of eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH).
Trial Locations
Location
Status
Location
Clinical Study Site
Leeds, United Kingdom, LS9 7TF
Status
N/A
Location
Research Site
Leeds, United Kingdom, LS9 7TF
Status
N/A
Location
Clinical Study Site
London, United Kingdom, SE5 9RS
Status
N/A
Location
Research Site
London, United Kingdom, SE5 9RS
Status
N/A